CTRI/2020/05/025068尚未招募3 期
A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicable
Christian Medical College Vellore0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Confirmed diagnosis of COVID19 infection based on +ve RTPCR
排除标准
- •Patients with other viral infections
研究者
相似试验
尚未招募
2 期
Comparison of two ways of using medications for preventing graft versus host disease after a half-matched stem cell transplantCTRI/2024/06/068451Indian Council of Medical Research
招募中
2 期
Effect of N-acetylcysteine to reduce occurrence of adverse drug reactions in patients receiving multi drug resistant tuberculosis in TanzaniaTuberculosisPACTR202007736854169Stellah Mpagama60
进行中（未招募）
1 期
ECX + Panitumumab vs. ECX alone in subjects with locally advanced gastric cancer or cancer of the gastroesophageal junctioSubjects with Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal JunctionMedDRA version: 18.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007798-18-DEAIO-Studien-gGmbH
招募中
2 期
The ROSEND Trial - A Randomised trial for the treatment of recalcitrant symptomatic rosacea using definitive volumetric modulated arc radiotherapy or standard dermatological treatmentACTRN12622001585718Icon Cancer Foundation40
进行中（未招募）
1 期
A phase II randomized, open label clinical trial in high risk percutaneous coronary intervention (PCI) patients receiving standard antithrombotic treatment plus either ALX-0081 or GPIIb/IIIa inhibitor (ReoPro®) over a period of 24 hoursEUCTR2009-012206-39-BEAblynx368